Anticoagulation in Peripheral Artery Disease: Are We There Yet?

Thromboembolism in patients with peripheral artery disease (PAD) represents a common cause of morbidity and mortality. In this article, the authors analyse the use of anticoagulants for patients with PAD. Anticoagulants have been used to reduce the risk of venous thromboembolism, but have recently b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alessandro Cannavale, Mariangela Santoni, Giuseppe Cannavale, Fabrizio Fanelli
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2020
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/47387b4264574583b7114302be76c14b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:47387b4264574583b7114302be76c14b
record_format	dspace
spelling	oai:doaj.org-article:47387b4264574583b7114302be76c14b2021-12-04T16:03:33ZAnticoagulation in Peripheral Artery Disease: Are We There Yet?10.15420/ver.2019.102516-33022516-3299https://doaj.org/article/47387b4264574583b7114302be76c14b2020-09-01T00:00:00Zhttps://www.verjournal.com/articles/anticoagulation-in-peripheral-artery-diseasehttps://doaj.org/toc/2516-3299https://doaj.org/toc/2516-3302Thromboembolism in patients with peripheral artery disease (PAD) represents a common cause of morbidity and mortality. In this article, the authors analyse the use of anticoagulants for patients with PAD. Anticoagulants have been used to reduce the risk of venous thromboembolism, but have recently been applied to the arterial circulation. Heparins were introduced to reduce short-term major adverse limb events in patients undergoing arterial revascularisation. Low molecular weight heparins have allowed easier management and carry a lower risk of bleeding than unfractioned heparin. Vitamin K anticoagulants have been tested in trials that included patients with PAD, showing an increased risk of bleeding when compared with aspirin alone, but longer patency rates for venous surgical bypass, although the evidence remains weak. Those anticoagulants are currently recommended only in patients with PAD who need anticoagulation for other diseases. Direct oral anticoagulants have only recently been investigated for use in patients with PAD. Promising results from low dose rivaroxaban plus aspirin have been recently outlined by a randomised controlled trial and supported by international guidelines.Alessandro CannavaleMariangela SantoniGiuseppe CannavaleFabrizio FanelliRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENVascular and Endovascular Review , Vol 3, Iss , Pp - (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Alessandro Cannavale Mariangela Santoni Giuseppe Cannavale Fabrizio Fanelli Anticoagulation in Peripheral Artery Disease: Are We There Yet?
description	Thromboembolism in patients with peripheral artery disease (PAD) represents a common cause of morbidity and mortality. In this article, the authors analyse the use of anticoagulants for patients with PAD. Anticoagulants have been used to reduce the risk of venous thromboembolism, but have recently been applied to the arterial circulation. Heparins were introduced to reduce short-term major adverse limb events in patients undergoing arterial revascularisation. Low molecular weight heparins have allowed easier management and carry a lower risk of bleeding than unfractioned heparin. Vitamin K anticoagulants have been tested in trials that included patients with PAD, showing an increased risk of bleeding when compared with aspirin alone, but longer patency rates for venous surgical bypass, although the evidence remains weak. Those anticoagulants are currently recommended only in patients with PAD who need anticoagulation for other diseases. Direct oral anticoagulants have only recently been investigated for use in patients with PAD. Promising results from low dose rivaroxaban plus aspirin have been recently outlined by a randomised controlled trial and supported by international guidelines.
format	article
author	Alessandro Cannavale Mariangela Santoni Giuseppe Cannavale Fabrizio Fanelli
author_facet	Alessandro Cannavale Mariangela Santoni Giuseppe Cannavale Fabrizio Fanelli
author_sort	Alessandro Cannavale
title	Anticoagulation in Peripheral Artery Disease: Are We There Yet?
title_short	Anticoagulation in Peripheral Artery Disease: Are We There Yet?
title_full	Anticoagulation in Peripheral Artery Disease: Are We There Yet?
title_fullStr	Anticoagulation in Peripheral Artery Disease: Are We There Yet?
title_full_unstemmed	Anticoagulation in Peripheral Artery Disease: Are We There Yet?
title_sort	anticoagulation in peripheral artery disease: are we there yet?
publisher	Radcliffe Medical Media
publishDate	2020
url	https://doaj.org/article/47387b4264574583b7114302be76c14b
work_keys_str_mv	AT alessandrocannavale anticoagulationinperipheralarterydiseasearewethereyet AT mariangelasantoni anticoagulationinperipheralarterydiseasearewethereyet AT giuseppecannavale anticoagulationinperipheralarterydiseasearewethereyet AT fabriziofanelli anticoagulationinperipheralarterydiseasearewethereyet
_version_	1718372731442954240

Anticoagulation in Peripheral Artery Disease: Are We There Yet?

Ejemplares similares